1,279
Participants
Start Date
February 25, 2016
Primary Completion Date
January 31, 2020
Study Completion Date
January 31, 2020
Golimumab Intravenous (IV)
This is an observational study. Patients who will receive golimumab IV will be observed for 3 years.
Infliximab
This is an observational study. Patients who will receive infliximab will be observed for 3 years.
Biosimilar Infliximab
This is an observational study. New patients who will receive biosimilar infliximab will be observed for 3 years (maximum). Biosimilar Infliximab patients will be included in Exploratory analyses only and will not be included in Primary or Secondary outcome measures analyses.
Birmingham
Huntsville
Glendale
Mesa
Peoria
Phoenix
Prescott
Sun City
Bakersfield
Campbell
Covina
El Cajon
Hemet
Los Angeles
Santa Cruz
Thousand Oaks
Upland
Van Nuys
West Hills
Whittier
Denver
Lakewood
Clearwater
Palm Harbor
Plantation
Tamarac
Venice
Lawrenceville
Springfield
Muncie
Bowling Green
Baton Rouge
Monroe
Shreveport
Cumberland
Hagerstown
Towson
Wheaton
Ann Arbor
Lansing
Saint Clair Shores
Eagan
Edina
Las Vegas
Nashua
Freehold
Voorhees Township
Brooklyn
Orchard Park
Greensboro
Leland
Raleigh
Winston-Salem
Edmond
Tulsa
Bethlehem
Duncansville
Philadelphia
Wexford
Myrtle Beach
Nashville
Amarillo
Beaumont
College Station
Corpus Christi
Dallas
Houston
Lubbock
Mesquite
Nassau Bay
Plano
San Antonio
San Marcos
Sugar Land
The Woodlands
Waco
Arlington
Chesapeake
Newport News
Kennewick
Seattle
Beckley
South Charleston
Glendale
Onalaska
Janssen Scientific Affairs, LLC
INDUSTRY